Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (5303)	7/9/1998 10:10:00 PM
From: Henry Niman	Respond to of 9719

OSI tries to get around prior art with the following claim: " bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect". Most of the earlier studies did target the hormone binding domain. The OSI patent was filed in 1995 so they appear to be focusing on "phantom effects" or allosteric changes which Ligand scientists have also described several years ago. Even this restricted claim may have some prior art problems.